North America Liquid Biopsy Market Size
The North America liquid biopsy market size was valued at US$2,350.78 million in 2026 and is estimated to US$7,097.58 million by 2033, growing at a CAGR of 17.1%.
Liquid biopsies are commonly used in oncology to detect and monitor cancer. The presence of circulating tumor DNA or other cancer-related biomarkers in the blood can provide information about the genetic characteristics of tumors, helping with diagnosis, treatment selection, and monitoring treatment response. Liquid biopsies have the potential to detect cancer at an earlier stage than traditional methods, as they can identify genetic alterations associated with tumors in their early development. Liquid biopsies enable real-time monitoring of genetic changes in tumors during the course of treatment. This information helps physicians make informed decisions about adjusting treatment strategies.
North America Liquid Biopsy Market Dynamics
Increasing investments and funding in liquid biopsy
The rise of investments can play a crucial role in driving the liquid biopsy market growth. Adequate funding can support the commercialization efforts of liquid biopsy companies.
This includes obtaining regulatory approvals, establishing manufacturing processes, and creating marketing strategies. Investments provide the necessary resources for these companies to bring their products to market efficiently. Thus, rise in investments and funding helps to boost the market growth. For instance, in October 2023, Aqtual liquid biopsy startup raised $16 million in Series A financing to further advance its cell-free DNA (cfDNA) analysis platform to develop blood-based assays to help select effective treatments for chronic diseases and cancer, starting with rheumatoid arthritis.
Additionally, in July 2022, Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, raised a Series B funding of $225 million. This funding will support the continued development and commercialization of high-quality and accessible blood tests for single-cancer early detection, multi-cancer early detection, and treatment monitoring.
Moreover in December 2023, researchers from the University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center received two grants totaling $9.1 million from the National Cancer Institute to advance liquid biopsy technologies for the early detection of cancer, which can significantly improve treatment outcomes and reduce the number of deaths caused by the disease. Thus, above factors help to boost the market growth.
North America Liquid Biopsy Market Opportunity
Rising opportunities in brain space
Liquid biopsy presents several opportunities in the diagnosis of brain tumors, offering a less invasive and potentially more accessible method for detecting and monitoring these complex and often challenging-to-diagnose conditions. For instance, the British Journal of Centre in 2023, stated that, in recent years, liquid biopsy has emerged as an alternative method to diagnose and monitor tumors. Compared to classical tissue biopsy procedures, liquid biopsy facilitates the repetitive collection of diverse cellular and acellular analytes from various biofluids in a non/minimally invasive manner.
This strategy is of greater significance for high-grade brain malignancies such as glioblastoma as the quantity and accessibility of tumors are limited, and there are collateral risks of compromised life quality coupled with surgical interventions.
Currently, blood and cerebrospinal fluid (CSF) are the most common biofluids used to collect circulating cells and biomolecules of tumor origin. These liquid biopsy analytes have created opportunities for real-time investigations of distinct genetic, epigenetic, transcriptomics, proteomics, and metabolomics alterations associated with brain tumors.
North America Liquid Biopsy Market Recent developments
- October 2026 – Grail advances Galleri toward FDA approval
Grail’s Galleri multi-cancer early detection blood test received preliminary support from a U.S. FDA advisory panel, bringing the liquid-biopsy-based cancer screening test closer to potential full FDA approval. The development could strengthen the role of blood-based testing in early cancer detection and expand adoption of liquid biopsy technologies in the U.S. - May 2026 – Guardant Health secures FDA approval for expanded Guardant360 Liquid CDx
Guardant Health received U.S. FDA approval for an expanded Guardant360 Liquid CDx, integrating genomic and epigenomic insights and providing a 100-fold wider genomic footprint than the previous Guardant360 CDx. The approval strengthens blood-based comprehensive genomic profiling for treatment selection in advanced cancer. - May 2026 – Natera receives FDA approval for Signatera CDx
The U.S. FDA approved Natera’s Signatera CDx as a personalized ctDNA-based assay for identifying molecular residual disease in patients with muscle-invasive bladder cancer and supporting treatment decisions involving Tecentriq therapies. The approval expands the clinical application of liquid biopsy for MRD assessment. - April 2026 – Guardant Health partners with Nuvalent on liquid biopsy companion diagnostics
Guardant Health entered a multi-year strategic collaboration with Nuvalent to use its tissue and liquid biopsy portfolio for clinical development and companion diagnostic strategies supporting targeted cancer therapies. The collaboration highlights the growing integration of liquid biopsy into oncology drug development and biomarker-driven treatment selection. - January 2026 – Guardant Health expands collaboration with Merck
Guardant Health and Merck announced a multi-year collaboration to use Guardant’s liquid and tissue biopsy technologies as clinical-trial enrollment assays and to explore companion diagnostics for Merck’s oncology portfolio. The partnership further supports the use of liquid biopsy in precision oncology and pharmaceutical clinical development. - January 2026 – NCI expands use of ctDNA in precision oncology trials
The National Cancer Institute updated the ComboMATCH clinical trial protocol to allow circulating tumor DNA sequencing to non-invasively screen patients for trial eligibility instead of relying exclusively on tumor tissue testing. The development demonstrates increasing adoption of liquid biopsy for molecular screening and precision-treatment selection in U.S. clinical research. - 2026 – CIRCULATE-NORTH AMERICA advances ctDNA-guided treatment research
The CIRCULATE-NORTH AMERICA study continues evaluating ctDNA to determine chemotherapy strategies for patients with stage II or III colon cancer following surgery. The trial is examining whether ctDNA status can guide treatment intensity and surveillance, supporting broader clinical adoption of liquid biopsy for minimal residual disease assessment. - 2026 – U.S. clinical research expands ctDNA-guided cancer treatment
Active U.S. studies are increasingly evaluating ctDNA for treatment response monitoring, molecular residual disease detection, and therapy selection across cancers including breast cancer, lymphoma, colorectal cancer, and sarcoma. These studies are helping move liquid biopsy applications beyond genomic profiling toward longitudinal disease monitoring and personalized treatment decisions.
North America Liquid Biopsy Market Segmentation
By Circulating Biomarker
- Circulating Tumor Cells
- Circulating Tumor DNA (ctDNA)/Cell-free DNA (cfDNA)
- Extracellular Vesicles
By Product & Services
- Kits & Reagents
- Instruments
- Services
By Application
- Cancer Applications
- Non-Cancer Applications
By Technology
- Multi-Gene-Parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)
By End User
- Hospitals and Physician Laboratories
- Research Centers
- Others
By Country
- US
- Canada
- Mexico
Key players
- Merck & Co, Inc
- F. Hoffmann-La Roche AG
- Exosome Diagnostics, Inc.
- Illumina Inc.
- Guardant Health Inc
- Thermo Fisher Scientific Inc.
- NeoGenomics Inc
- Qiagen NV
- BioChain Institute Inc.
- Biocept Inc.
Why Purchase the Report?
- To visualize the North America Liquid Biopsy Market segmentation based on the circulating biomarker, product & services, application, technology, end-user, and region and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous liquid biopsy market-level data points with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The North America Liquid Biopsy Market Report Would Provide Approximately 77 Tables, 77 Figures, and 195 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
